Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY

Recruiting now

Conditions studied: Papillary Thyroid Cancer

In brief

Somatic mutations in the MAP (mitogen-activated protein) kinase pathway have been found in about 80% of papillary thyroid tumors (PTCs). The evaluation of the PTC mutational profile is crucial for the definition of the prognosis and for predicting the effects of targeted and personalized therapies. Molecular characterization by mass spectrometry (Mass ARRAY) allows the search for multiple mutations in a single experiment, in a sensitive, fast and economic way. A Mass ARRAY platform (PTC-MA) was developed, capable of identifying the presence of the most common somatic point mutations and rearrangements in PTC (Pesenti et al., Endocrine 2017). The aim of the study is to characterize the mutational profile of a large series of papillary thyroid carcinomas (PTC). Tumor samples will be analyzed using our PTC-MA platform. The molecular profile of PTCs will be correlated with the clinical and prognostic characteristics of the patients.

Key facts

Study ID

NCT05766098

Run by

Istituto Auxologico Italiano

People needed

600

Starts

2019-01-08

Expected to finish

2027-12-31

Last updated by the study team

2024-10-08

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients with papillary thyroid cancer
• patients whose tumor tissue can be recovered for genetic analysis

You may not qualify if…

• patients who did not give consent
• patients lost to follow-up
• tumor samples not suitable for genetic analysis

Where it is running

• Istituto Auxologico Italiano — Milan, MI, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.